Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1R132H Glioma Cell Lines
Pharmaceuticals · 28.02.2026 · 19 (3) · 392
DOI: 10.3390/ph19030392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 28.02.2026. Verfasst von Cristiana Alberghina und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioimaging and Complex Biological Systems, National Research Council, 90015 Cefalù, Italy. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Piano di Incentivi per la Ricerca di Ateneo 2020-2022 - PIA.CE.RI. 2020-2022-Linea di intervento 3-Starting Grant MINDS, funding of research initiatives for technologies and innovative trajectories in the health and care sectors (Directorial Decree n. 931 of 06-06-2022)-project n…, Research was also partially funded by Région Normandy RIN TREMPLIN CHOxTRaCC.
Abstract (Originalsprache)
Background
Adult diffuse gliomas represent one of the most aggressive types of brain tumors. Proton therapy offers a minimally invasive treatment option whose biological effectiveness may be enhanced through nuclear reactions involving boron atoms, leading to the emission of high-LET α-particles. In this study, we investigated the potential enhancement of radiation-induced damage of a novel boron-conjugated, ATP-competitive SRC kinase inhibitor, in the U-87 MG glioma cell line and its isogenic cell line stably expressing the IDH1 R132H mutation.
Methods
Glioma cells were exposed to either proton or X-ray irradiation to assess whether any enhancement associated with this boron-delivery strategy was specific to proton interactions. Cell survival assays and analyses of DNA damage responses were conducted in both cell lines.
Results
While no significant synergistic effects were observed in survival endpoints, differences emerged at the level of early DNA damage effects, with IDH1-mutant glioma cells displaying an enhanced acute response following combined treatment with proton irradiation.
Conclusions
These findings support further pharmacological development of boron-based SRC-targeted strategies and underscore the importance of tailoring therapeutic approaches to specific glioma molecular subtypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Bioimaging and Complex Biological Systems, National Research Council, 90015 Cefalù, Italy.
- National Institute for Nuclear Physics (INFN), Laboratori Nazionali del Sud, 95123 Catania, Italy.
- Department of Pharmaceutical and Health Sciences, University of Catania, 95123 Catania, Italy.
- ISTCT UMR6030, CYCERON, University of Caen Normandy, CNRS, Normandy University, 14000 Caen, France.
- Department of Medical Physics, Centre François Baclesse, 14000 Caen, France.
- Department of Ecological and Biological Sciences, University of Tuscia, 01100 Viterbo, Italy.
ORCID-Profile: Filippo Torrisi, Samuel Valable, Valentina Bravatà, Lorenzo Botta, Luca Lanzanò, Rosalba Parenti
Förderung
- Piano di Incentivi per la Ricerca di Ateneo 2020-2022 - PIA.CE.RI. 2020-2022-Linea di intervento 3-Starting Grant MINDS
- funding of research initiatives for technologies and innovative trajectories in the health and care sectors (Directorial Decree n. 931 of 06-06-2022)-project n…
- Research was also partially funded by Région Normandy RIN TREMPLIN CHOxTRaCC
Zitieren
APA
Alberghina, C., Torrisi, F., Valable, S., Sarrazin, E., Blanchard, I., Vela, A., Bravatà, V., Botta, L., Lanzanò, L., Scalisi, S., Demichelis, M. P., Sabini, M. G., Patti, I. V., Russo, G., Cammarata, F. P., & Parenti, R. (2026). Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1R132H Glioma Cell Lines. Pharmaceuticals, 19(3), 392. https://doi.org/10.3390/ph19030392
Vancouver
Alberghina C, Torrisi F, Valable S, Sarrazin E, Blanchard I, Vela A, et al. Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1R132H Glioma Cell Lines. Pharmaceuticals. 2026;19(3):392. doi:10.3390/ph19030392
BibTeX
@article{Alberghina2026,
author = {Alberghina, Cristiana and Torrisi, Filippo and Valable, Samuel and Sarrazin, Elsa and Blanchard, Isis and Vela, Anthony and Bravatà, Valentina and Botta, Lorenzo and Lanzanò, Luca and Scalisi, Silvia and Demichelis, Maria P and Sabini, Maria G and Patti, Iolanda V and Russo, Giorgio and Cammarata, Francesco P and Parenti, Rosalba},
title = {Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1R132H Glioma Cell Lines},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {3},
pages = {392},
doi = {10.3390/ph19030392}
}
EUVIMED